Acorda Therapeutics Inc (ACOR) Given Average Rating of “Hold” by Analysts

Shares of Acorda Therapeutics Inc (NASDAQ:ACOR) have earned an average rating of “Hold” from the eighteen brokerages that are currently covering the company, MarketBeat reports. Four investment analysts have rated the stock with a sell rating, ten have issued a hold rating, two have issued a buy rating and one has given a strong buy rating to the company. The average 1 year target price among brokerages that have updated their coverage on the stock in the last year is $21.30.

A number of research analysts recently commented on the company. HC Wainwright restated a “buy” rating and set a $31.00 price objective (down from $34.00) on shares of Acorda Therapeutics in a research note on Wednesday. Zacks Investment Research downgraded Acorda Therapeutics from a “hold” rating to a “sell” rating in a research note on Wednesday, January 10th. JPMorgan Chase & Co. reissued a “hold” rating on shares of Acorda Therapeutics in a research note on Tuesday, January 9th. Piper Jaffray Companies reissued a “neutral” rating and issued a $22.00 price target on shares of Acorda Therapeutics in a research note on Tuesday, November 28th. Finally, TheStreet cut Acorda Therapeutics from a “c-” rating to a “d+” rating in a research note on Friday, November 17th.

Shares of Acorda Therapeutics (NASDAQ ACOR) traded up $2.20 on Friday, reaching $27.20. The company had a trading volume of 3,986,832 shares, compared to its average volume of 619,734. The company has a market cap of $1,168.68, a P/E ratio of -22.48 and a beta of 1.58. The company has a debt-to-equity ratio of 0.49, a quick ratio of 2.40 and a current ratio of 2.77. Acorda Therapeutics has a 52-week low of $13.60 and a 52-week high of $33.00.

Acorda Therapeutics (NASDAQ:ACOR) last issued its quarterly earnings data on Tuesday, October 31st. The biopharmaceutical company reported $0.43 EPS for the quarter, missing the Zacks’ consensus estimate of $0.69 by ($0.26). The company had revenue of $141.07 million for the quarter, compared to the consensus estimate of $150.64 million. Acorda Therapeutics had a negative return on equity of 8.18% and a negative net margin of 10.25%. Acorda Therapeutics’s quarterly revenue was up 4.0% compared to the same quarter last year. During the same quarter in the previous year, the company earned ($0.04) earnings per share. equities analysts predict that Acorda Therapeutics will post 0.02 EPS for the current year.

In other news, insider Burkhard Blank sold 11,050 shares of the company’s stock in a transaction on Friday, December 1st. The stock was sold at an average price of $20.53, for a total value of $226,856.50. Following the completion of the sale, the insider now owns 33,150 shares in the company, valued at $680,569.50. The sale was disclosed in a legal filing with the SEC, which is available at this link. Corporate insiders own 7.90% of the company’s stock.

Institutional investors have recently made changes to their positions in the company. Piedmont Investment Advisors LLC acquired a new stake in shares of Acorda Therapeutics in the second quarter valued at $199,000. Laurion Capital Management LP acquired a new stake in shares of Acorda Therapeutics in the second quarter valued at $219,000. Crossmark Global Holdings Inc. acquired a new stake in shares of Acorda Therapeutics in the third quarter valued at $233,000. Voya Investment Management LLC lifted its holdings in shares of Acorda Therapeutics by 10.1% in the second quarter. Voya Investment Management LLC now owns 20,633 shares of the biopharmaceutical company’s stock valued at $406,000 after buying an additional 1,897 shares during the period. Finally, Municipal Employees Retirement System of Michigan lifted its holdings in shares of Acorda Therapeutics by 59.8% in the third quarter. Municipal Employees Retirement System of Michigan now owns 17,510 shares of the biopharmaceutical company’s stock valued at $414,000 after buying an additional 6,550 shares during the period.

ILLEGAL ACTIVITY WARNING: “Acorda Therapeutics Inc (ACOR) Given Average Rating of “Hold” by Analysts” was originally posted by American Banking News and is owned by of American Banking News. If you are accessing this story on another domain, it was stolen and republished in violation of international copyright and trademark legislation. The legal version of this story can be viewed at https://www.americanbankingnews.com/2018/01/20/acorda-therapeutics-inc-acor-given-average-rating-of-hold-by-analysts.html.

About Acorda Therapeutics

Acorda Therapeutics, Inc is a biopharmaceutical company. The Company focuses on developing therapies that restore function and improve the lives of people with neurological disorders. As of December 31, 2016, the Company marketed three United States Food and Drug Administration (FDA)-approved therapies, including Ampyra (dalfampridine) Extended Release Tablets, 10 milligram (mg), a treatment to improve walking in patients with multiple sclerosis (MS).

Analyst Recommendations for Acorda Therapeutics (NASDAQ:ACOR)

Receive News & Ratings for Acorda Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acorda Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply